Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Momelotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 20/20 | 0.93 |
| ▸ | JAK1 known ✓ | P23458 | 10/20 | 0.93 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.93 |
| ▸ | JAK3 | P52333 | 16/20 | 0.93 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.93 |
| ▸ | TYK2 | P29597 | 2/20 | 0.93 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.93 |
| ▸ | PLK4 | O00444 | 1/20 | 0.93 |
| ▸ | CIT | O14578 | 1/20 | 0.93 |
| ▸ | GAK | O14976 | 1/20 | 0.93 |
| ▸ | OPA1 | O60313 | 1/20 | 0.93 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.93 |
| ▸ | STK16 | O75716 | 1/20 | 0.93 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.93 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.93 |
| ▸ | CDK2 | P24941 | 1/20 | 0.93 |
| ▸ | MARK3 | P27448 | 1/20 | 0.93 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.93 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.93 |
| ▸ | STAT3 | P40763 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Momelotinib SCHEMBL3619662 | 1.00 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL30051896 | 0.98 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL22282523 | 0.97 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2237234 | 0.97 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL29352115 | 0.97 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL17333087 | 0.96 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863013 | 0.96 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL29774318 | 0.96 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863022 | 0.96 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| SCHEMBL2858799 | 0.91 | JAK2 (0.89) | JAK2JAK3JAK1HDAC1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2152701-B1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2015-11-11 | — | — | EP | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885ACVR1 911/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.